Skip to main content

Table 6 SF-36 scores (higher scores indicate less impairment).

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

  

Baseline

SAMe

Celecoxib

 

Variable

N+

Mean

(SD)

Mean

(SD)

Mean

(SD)

Stdif.

Physical Function

53

52.5

(20.8)

62.4*

(22.8)

63.7*

(25.1)

-0.10

Role Physical

53

56.6

(37.4)

66.5*

(33.6)

67.9*

(38.1)

-0.04

Role Emotional

53

86.8

(29.5)

88.7

(24.4)

87.4

(27.1)

0.06

Vitality

53

58.9

(14.4)

60.4

(14.0)

62.9*

(14.5)

-0.23

Mental Health

53

71.8

(11.4)

73.7

(11.3)

74.0

(11.8)

-0.03

Social Function

53

82.3

(20.1)

84.2

(19.8)

86.3

(18.7)

-0.09

Bodily Pain

53

46.8

(14.1)

59.3*

(19.8)

63.1*

(19.6)

-0.16

General Health

53

74.6

(15.2)

75.4

(17.2)

76.6

(16.8)

-0.10

General Physical

53

38.1

(8.2)

42.3*

(9.5)

43.4*

(10.6)

-0.16

General Mental

53

54.6

(7.8)

54.1

(7.4)

54.2

(6.8)

-0.02

  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us